FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.
February 08, 2018 18:30 ET
|
Xeris Pharmaceuticals, Inc.
Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) --
Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
Xeris Pharmaceuticals Presents Non-Aqueous Glucagon Stability Data at the American Diabetes Association 73nd Scientific Sessions
June 21, 2013 10:00 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, June 21, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that it is
presenting at the American Diabetes Association 73nd Scientific
Sessions in Chicago, IL...